SL1009 (sodium dichloroacetate)

Name: SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Pharmacodynamics
Published: 2026-09-14T15:39:06-04:00

Pyruvate dehydrogenase complex deficiency

Manufacturer: Saol Therapeutics
Regulatory submission: NDA resubmitted June 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Pharmacology

Pharmacodynamics

3 evidence topics · 6 sources

Preclinical peripheral nerve effects

“Both juvenile and adult rats treated with DCA developed nerve conduction slowing that was more pronounced in adult rats.” (opens the source at this quote in a new tab)

Preclinical nematode model: preprint

“Significantly improved health, survival, tissue lactate levels, and mitochondrial physiology were observed at 25 mM in pdha-1(RNAi) knockdown animals.” (opens the source at this quote in a new tab)

Historical clinical review of dichloroacetate response

“The case histories of 46 subjects were analyzed with regard to diagnosis, clinical presentation and response to DCA.” (opens the source at this quote in a new tab)